Aline Martin

List of Publications by Year
in descending order

23 papers	2,494 citations	471509 17 h-index	642732 23 g-index
23 all docs	23 docs citations	23 times ranked	2959 citing authors

#	Article	IF	Citations
1	Regulation and Function of the FGF23/Klotho Endocrine Pathways. Physiological Reviews, 2012, 92, 131-155.	28.8	471
2	Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metabolism, 2015, 22, 1020-1032.	16.2	432
3	Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney International, 2016, 89, 135-146.	5.2	370
4	Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB Journal, 2011, 25, 2551-2562.	0.5	228
5	A Comparative Transcriptome Analysis Identifying FGF23 Regulated Genes in the Kidney of a Mouse CKD Model. PLoS ONE, 2012, 7, e44161.	2.5	164
6	Degradation of MEPE, DMP1, and Release of SIBLING ASARM-Peptides (Minhibins): ASARM-Peptide(s) Are Directly Responsible for Defective Mineralization in HYP. Endocrinology, 2008, 149, 1757-1772.	2.8	155
7	Leptin Modulates both Resorption and Formation while Preventing Disuse-Induced Bone Loss in Tail-Suspended Female Rats. Endocrinology, 2005, 146, 3652-3659.	2.8	118
8	Opposite Effects of Leptin on Bone Metabolism: A Dose-Dependent Balance Related to Energy Intake and Insulin-Like Growth Factor-I Pathway. Endocrinology, 2007, 148, 3419-3425.	2.8	98
9	Matrix Extracellular Phosphoglycoprotein (MEPE) Is a New Bone Renal Hormone and Vascularization Modulator. Endocrinology, 2009, 150, 4012-4023.	2.8	91
10	Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness. Journal of the American Society of Nephrology: JASN, 2017, 28, 1877-1885.	6.1	76
11	DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease. Bone Research, 2019, 7, 12.	11.4	57
12	Angiotensin-converting enzyme 2 amplification limitedÂto the circulation does not protect miceÂfromÂdevelopment of diabetic nephropathy. Kidney International, 2017, 91, 1336-1346.	5.2	49
13	Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function inÂaÂmouse model of chronic kidney disease. Kidney International, 2019, 96, 1346-1358.	5.2	47
14	Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal Tubule. PLoS ONE, 2015, 10, e0142924.	2.5	26
15	Genetic background influences cardiac phenotype in murine chronic kidney disease. Nephrology Dialysis Transplantation, 2018, 33, 1129-1137.	0.7	26
16	Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease. Bone Research, 2021, 9, 35.	11.4	24
17	Fat and Sucrose Intake Induces Obesity-Related Bone Metabolism Disturbances: Kinetic and Reversibility Studies in Growing and Adult Rats. Journal of Bone and Mineral Research, 2016, 31, 98-115.	2.8	23
18	Hypophosphatemic rickets accelerate chondrogenesis and cell trans-differentiation from TMJ chondrocytes into bone cells via a sharp increase in Î²-catenin. Bone, 2020, 131, 115151.	2.9	11

#	Article	IF	Citations
19	Bone and heart health in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2019, 28, 297-303.	2.0	9
20	Antagonism Between PEDF and TGF-Î² Contributes to Type VI Osteogenesis Imperfecta Bone and Vascular Pathogenesis. Journal of Bone and Mineral Research, 2020, 37, 925-937.	2.8	7
21	Longâ€Term Effects of <scp>Sglt2</scp> Deletion on Bone and Mineral Metabolism in Mice. JBMR Plus, 2021, 5, e10526.	2.7	5
22	The Role of DMP1 in CKD-MBD. Current Osteoporosis Reports, 2021, 19, 500-509.	3.6	4
23	Transcriptomics: a Solution for Renal Osteodystrophy?. Current Osteoporosis Reports, 2020, 18, 254-261.	3.6	3